

Amendments to the Claims:

Listing of Claims:

Claims 1-4 (canceled)

Claim 5 (currently amended): A method of treating a human subject suffering from pulmonary fibrosis disease which comprises administering to a said human in need of such treatment a dose, effective against pulmonary fibrosis, of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phenyl]-benzamide of the formula I or a pharmaceutically acceptable salt thereof.

Claim 6 (currently amended): ~~Use according to any one of claims 1 to 4 or~~The method according to claim 5 wherein the pulmonary fibrosis disease is induced by asbestos.

Claim 7 (currently amended): A method of administering to a human subject suffering from pulmonary fibrosis disease which comprises administering a pharmaceutically effective amount of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-yl-amino]phenyl]-benzamide of the formula I or a pharmaceutically acceptable salt thereof to said human subject once daily for a period exceeding 3 months.

Claim 8 (currently amended): ~~Use of~~The method according to ~~any one of claims 1 to 7~~claim 7 wherein 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-yl-amino]phenyl]-benzamide of the formula I is in the form of a pharmaceutically acceptable acid addition salt thereof.

Claim 9 (currently amended): ~~Use of~~The method according to claim 8 wherein 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phenyl]-benzamide of the formula I is in the monomethane sulfonate salt form thereof.

Claim 10 (currently amended): ~~Use of~~The method according to claim 9 wherein 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phenyl]-benzamide of the formula I is in the beta crystal form of the mesylate salt.

Claim 11 (currently amended): ~~Use or method according to claim 11 wherein~~ A method of administering to a human subject suffering from pulmonary fibrosis disease which comprises administering a daily dose of a monomethanesulfonate salt of 4-(4-methylpiperazin-1-

ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phenyl]-benzamide of the formula I in the beta crystal form corresponding to 200 to 800 mg of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phenyl]-benzamide of the formula I free base is administered to an adult human.

Claim 12 (new): The method according to claim 5 wherein the pulmonary fibrosis disease is an interstitial lung disease.

Claim 13 (new): The method according to claim 5 wherein the pulmonary fibrosis disease is an idiopathic pulmonary fibrosis.